Alvotech SDB (ALVO.SDB)
Market Open
XSTO XSTO Primary kr
kr
9.63B Market Cap
- P/E Ratio
- Div Yield
- Volume
0 Eps
kr
Previous Close Want to track ALVO.SDB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ALVO.SDB is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
Alvotech SDB (ALVO.SDB) FAQ
What is the stock price today?
The current price is kr0.00.
On which exchange is it traded?
Alvotech SDB is listed on XSTO.
What is its stock symbol?
The ticker symbol is ALVO.SDB.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 9.63B.
Has Alvotech SDB ever had a stock split?
No, there has never been a stock split.
Alvotech SDB Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Robert Wessman CEO | XSTO Exchange | - ISIN |
| US Country | 999 Employees | - Last Dividend | - Last Split | 16 Jun 2022 IPO Date |
Overview
Alvotech is a prominent player in the pharmaceutical industry, specializing in the development and manufacturing of biosimilar medicines with a global outreach to serve patients. With its foundation laid in 2013 and headquartered in Luxembourg, Luxembourg, the company focuses on delivering high-quality biosimilar products across various therapeutic areas. These areas include autoimmune diseases, eye and bone disorders, and cancer treatments, thereby substantiating its commitment to improving patient care and accessibility to essential medicines.
Products and Services
- AVT02: A high concentration formulation biosimilar to Humira, designed to treat a broad range of inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. This flagship product highlights Alvotech’s determination to address critical areas of patient need.
- AVT04: A biosimilar to Stelara, targeted at various inflammatory conditions including psoriatic arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. The development of AVT04 underscores Alvotech’s comprehensive approach to inflammatory diseases.
- AVT06: Aimed at treating eye conditions such as age-related macular degeneration, macular edema, and diabetic retinopathy, AVT06 is a biosimilar to Eylea. This product exemplifies Alvotech's expansion into opthalmic solutions.
- AVT03: In the pre-clinical phase, this biosimilar to Xgeva and Prolia is being developed to prevent bone fractures, spinal cord compression, or the need for radiation or bone surgery in certain cancer patients, as well as to prevent bone loss and increase bone mass.
- AVT05: Early phase development of a biosimilar to Simponi and Simponi Aria for treating various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. This demonstrates Alvotech’s ambition to broaden its portfolio in autoimmune treatments.
- AVT16: A biosimilar to an Entyvio product, signifying Alvotech’s entry into gastrointestinal treatment solutions.
- AVT23: In late-stage development, this biosimilar to Xolair aims to treat nasal polyps, reflecting Alvotech’s interest in addressing respiratory conditions.
- AVT33: A biosimilar to a Keytruda product, this entry signifies Alvotech's venture into cancer therapy, aiming to deliver more accessible options for cancer patients worldwide.
Contact Information
Address: 9, Rue de Bitbourg, Luxembourg City, Luxembourg, 1273
Phone: 354 422 4500
Website: https://www.alvotech.com
